332 related articles for article (PubMed ID: 9740292)
1. A thirty day course of sodium stibogluconate for treatment of Kala-azar in Nepal.
Karki P; Koirala S; Parija SC; Hansdak SG; Das ML
Southeast Asian J Trop Med Public Health; 1998 Mar; 29(1):154-8. PubMed ID: 9740292
[TBL] [Abstract][Full Text] [Related]
2. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya.
Moore E; O'Flaherty D; Heuvelmans H; Seaman J; Veeken H; de Wit S; Davidson RN
Bull World Health Organ; 2001; 79(5):388-93. PubMed ID: 11417033
[TBL] [Abstract][Full Text] [Related]
3. Observations on the effect of verapamil with sodium stibogluconate in kala azar.
Thakur CP; Kumar M
Trop Geogr Med; 1992 Jan; 44(1-2):15-8. PubMed ID: 1323160
[TBL] [Abstract][Full Text] [Related]
4. Comparison of treatment regimens of kala-azar based on culture & sensitivity of amastigotes to sodium antimony gluconate.
Thakur CP; Thakur S; Narayan S; Sinha A
Indian J Med Res; 2008 Jun; 127(6):582-8. PubMed ID: 18765878
[TBL] [Abstract][Full Text] [Related]
5. Clinical risk factors for therapeutic failure in kala-azar patients treated with pentavalent antimonials in Nepal.
Rijal S; Bhandari S; Koirala S; Singh R; Khanal B; Loutan L; Dujardin JC; Boelaert M; Chappuis F
Trans R Soc Trop Med Hyg; 2010 Mar; 104(3):225-9. PubMed ID: 19726065
[TBL] [Abstract][Full Text] [Related]
6. PCR for diagnosis and assessment of cure in kala-azar patients in Bangladesh.
Salam MA; Mondal D; Kabir M; Ekram AR; Haque R
Acta Trop; 2010 Jan; 113(1):52-5. PubMed ID: 19769932
[TBL] [Abstract][Full Text] [Related]
7. Experience with amphotericin B in sodium stibogluconate--unresponsive cases of visceral Leishmaniasis in north Bihar.
Giri OP; Singh AN
J Assoc Physicians India; 1994 Sep; 42(9):690-1. PubMed ID: 7883660
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy in Kala-azar.
Singh NK; Jha TK; Singh IJ; Jha S
J Assoc Physicians India; 1995 May; 43(5):319-20. PubMed ID: 9081958
[TBL] [Abstract][Full Text] [Related]
9. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.
Das VN; Ranjan A; Bimal S; Siddique NA; Pandey K; Kumar N; Verma N; Singh VP; Sinha PK; Bhattacharya SK
Natl Med J India; 2005; 18(3):131-3. PubMed ID: 16130613
[TBL] [Abstract][Full Text] [Related]
10. Cumulative cardiac toxicity of sodium stibogluconate and amphotericin B in treatment of kala-azar.
Maheshwari A; Seth A; Kaur S; Aneja S; Rath B; Basu S; Patel R; Dutta AK
Pediatr Infect Dis J; 2011 Feb; 30(2):180-1. PubMed ID: 20823781
[TBL] [Abstract][Full Text] [Related]
11. A retrospective study of intravenous sodium stibogluconate alone and in combinations with allopurinol, rifampicin, and an immunomodulator in the treatment of Indian post-kala-azar dermal leishmaniasis.
Ramesh V; Kumar J; Kumar D; Salotra P
Indian J Dermatol Venereol Leprol; 2010; 76(2):138-44. PubMed ID: 20228542
[TBL] [Abstract][Full Text] [Related]
12. Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy.
Melaku Y; Collin SM; Keus K; Gatluak F; Ritmeijer K; Davidson RN
Am J Trop Med Hyg; 2007 Jul; 77(1):89-94. PubMed ID: 17620635
[TBL] [Abstract][Full Text] [Related]
13. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of amphotericin B as a first line drug in comparison to sodium stibogluconate in the treatment of fresh cases of kala-azar.
Thakur CP; Sinha GP; Sharma V; Pandey AK; Kumar M; Verma BB
Indian J Med Res; 1993 Jul; 97():170-5. PubMed ID: 8406644
[TBL] [Abstract][Full Text] [Related]
15. Post-kala-azar dermal leishmaniasis (PKDL): the first case report from Nepal.
Karki P; Koirala S; Parija SC; Sethi M; Das ML
Southeast Asian J Trop Med Public Health; 2003 Mar; 34(1):22-3. PubMed ID: 12971510
[TBL] [Abstract][Full Text] [Related]
16. Clinical and laboratory study of kala-azar in children in Nepal.
Singh K; Singh R; Parija SC; Faridi MM; Bhatta N
J Trop Pediatr; 1999 Apr; 45(2):95-7. PubMed ID: 10341503
[TBL] [Abstract][Full Text] [Related]
17. Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine.
Sundar S; Kumar K; Chakravarty J; Agrawal D; Agrawal S; Chhabra A; Singh V
Trans R Soc Trop Med Hyg; 2006 Jul; 100(7):698-700. PubMed ID: 16325873
[TBL] [Abstract][Full Text] [Related]
18. Sodium stibogluconate-sensitive visceral leishmaniasis in the non-endemic hilly region of Uttarakhand, India.
Verma SK; Ahmad S; Shirazi N; Kusum A; Kaushik RM; Barthwal SP
Trans R Soc Trop Med Hyg; 2007 Jul; 101(7):730-2. PubMed ID: 17382981
[TBL] [Abstract][Full Text] [Related]
19. Problems in the treatment of kala-azar: case report.
Nyakundi PM; Rashid JR; Wasunna KM; Were JB; Muigai R; Kirigi G; Mbugua J
East Afr Med J; 1995 Jun; 72(6):406-8. PubMed ID: 7498017
[TBL] [Abstract][Full Text] [Related]
20. Visceral Leishmaniasis in children in the Yemen.
Haidar NA; Diab AB; El-Sheik AM
Saudi Med J; 2001 Jun; 22(6):516-9. PubMed ID: 11426243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
